๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced or Metastatic Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site๐Ÿ“ Taipei PhytoHealth Corporation ยท Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer NCT07455188n/a1 site๐Ÿ“ Zhejiang Zhejiang Cancer Hospital ยท Tests: Antitumor treatment plan Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy NCT06998108Phase 31 site๐Ÿ“ Beijing BeBetter Med Inc ยท Tests: BEBT-209 capsules, BEBT-209 Placebo capluses, Fulvestrant Injection Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites๐Ÿ“ Jonesboro๐Ÿ“ Little Rock๐Ÿ“ Duarte Celcuity Inc ยท Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letโ€ฆ AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527Phase 31 site๐Ÿ“ Beijing Akeso ยท Tests: AK112, Nab-paclitaxel, Placebo A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites๐Ÿ“ Los Angeles๐Ÿ“ Sarasota๐Ÿ“ St Louis Angiex, Inc. ยท Tests: AGX101 Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites๐Ÿ“ Fuzhou๐Ÿ“ Guangzhou๐Ÿ“ Guiyang Shanghai Pharmaceuticals Holding Co., Ltd ยท Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270Phase 12 sites๐Ÿ“ Zhengzhou๐Ÿ“ Shanghai Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd ยท Tests: SYN818 Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients NCT06690840Phase 25 sites๐Ÿ“ Monza๐Ÿ“ Roma๐Ÿ“ Roma European Institute of Oncology ยท Tests: Atezolizumab in combination with Cyclophosphamide and Vinorelbine A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06493864Phase 11 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B16D1 A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Hefei Genor Biopharma Co., Ltd. ยท Tests: GB491 combined with Letrozole, Placebo combined with Letrozole A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site๐Ÿ“ Beijing Shenzhen Majory Biotechnology Co., Ltd. ยท Tests: MR001 Bispecific Antibody for Injection A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites๐Ÿ“ Los Angeles๐Ÿ“ Lone Tree๐Ÿ“ Springfield Faeth Therapeutics ยท Tests: Serabelisib, Sapanisertib, Fulvestrant A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ๏ผšSingle-arm, Prospective, Open Clinical Study NCT06125080Phase 21 site๐Ÿ“ Wuhan Huihua Xiong ยท Tests: Utidelone, Tirelizumab, Bevacizumab An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites๐Ÿ“ Tucson๐Ÿ“ Hot Springs๐Ÿ“ Little Rock AstraZeneca ยท Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EBNK-001 + IL-15 + Pembrolizumab A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: ATRA, Toripalimab RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939Phase 2, Phase 3206 sites๐Ÿ“ Huntsville๐Ÿ“ Gilbert๐Ÿ“ San Francisco Hoffmann-La Roche ยท Tests: RO7771950, Tucatinib, Trastuzumab, Capecitabine Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site๐Ÿ“ San Francisco Laura Huppert, MD, BA ยท Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management NCT05362760Phase 454 sites๐Ÿ“ Aalen๐Ÿ“ Amberg๐Ÿ“ Aschaffenburg Prof. Wolfgang Janni ยท Tests: Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer NCT07205822Phase 340 sites๐Ÿ“ Largo๐Ÿ“ Fort Wayne๐Ÿ“ Omaha AstraZeneca ยท Tests: Dato-DXd Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ยฑ Toripalimab in HR-/HER2-low Breast Cancer NCT06642545Phase 21 site๐Ÿ“ Beijing RemeGen Co., Ltd. ยท Tests: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone, Toripalimab GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites๐Ÿ“ Goyang-si๐Ÿ“ Seoul๐Ÿ“ Seoul GeneMedicine Co., Ltd. ยท Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer NCT07766018Phase 219 sites๐Ÿ“ Chiba๐Ÿ“ Fukuoka๐Ÿ“ Fukuoka Stemline Therapeutics, Inc. ยท Tests: Elacestrant
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy